CVR: 41244909
DKK -74,484
Gross profit
Net result: DKK -972,747
No owners listed
CVR · view ownership and management
Director role ended: Søren Sylvester Skjærbæk
CVR · 14/01/2025
View the full event history
HyperBio Therapeutics ApS was a Danish company of the type Anpartsselskab based in Vejle Øst, founded in 2020 and dissolved in 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. In 2023, the company reported a gross profit of DKK -74,484 and a net result of DKK -972,747 compared with DKK -7,656,366 the year before. Equity in the 2023 report amounted to DKK 739,784.
Source: annual reports filed with the Danish Business Authority.
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningNo. HyperBio Therapeutics ApS is registered in the Danish CVR register with the status Dissolved and ceased on 14 January 2025.
HyperBio Therapeutics ApS was founded on 12 March 2020.
HyperBio Therapeutics ApS was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (industry code 721000).
In 2023, HyperBio Therapeutics ApS reported a gross profit of DKK -74,484.
HyperBio Therapeutics ApS was located at c/o Ursus Law Firm, Stærmosevej 12, 7120 Vejle Øst.
The CVR number of HyperBio Therapeutics ApS is 41244909.
As of January 14, 2025, Søren Sylvester Skjærbæk has stepped down as liquidator of HyperBio Therapeutics ApS.
On January 14, 2025, HyperBio Therapeutics ApS exited liquidation.
HyperBio Therapeutics ApS was dissolved on January 14, 2025.
As of July 2, 2024, Søren Sylvester Skjærbæk is registered as liquidator of HyperBio Therapeutics ApS.
As of July 2, 2024, Søren Sylvester Skjærbæk has stepped down as director of HyperBio Therapeutics ApS.
As of July 2, 2024, Morten Døssing has stepped down as chairman of HyperBio Therapeutics ApS.
On July 2, 2024, HyperBio Therapeutics ApS entered liquidation.
HyperBio Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -74,484, and the net result was DKK -972,747.
HyperBio Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -8,628,935, and the net result was DKK -7,656,366.
As of June 9, 2023, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has stepped down as auditor of HyperBio Therapeutics ApS.
HyperBio Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -12,881,904, and the net result was DKK -10,612,873.
As of June 18, 2021, Niccolo' Bacchi-Bønnelykke has left the board of directors of HyperBio Therapeutics ApS.
HyperBio Therapeutics ApS has published its interim report for the period March 12, 2020 – December 31, 2020.
As of March 12, 2020, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has been appointed auditor of HyperBio Therapeutics ApS.
As of March 12, 2020, Niccolo' Bacchi-Bønnelykke has joined the board of directors of HyperBio Therapeutics ApS.
As of March 12, 2020, Søren Sylvester Skjærbæk is registered as director of HyperBio Therapeutics ApS.
As of March 12, 2020, Morten Døssing is registered as chairman of HyperBio Therapeutics ApS.
HyperBio Therapeutics ApS was founded on March 12, 2020.
Companies in the same industry and area
CVR 30738276
CVR 25577922
CVR 29428514
CVR 42036099
CVR 44395665
